RxDoctor Payments Data

Christine Dong, MD

Neurology · Hermitage, TNNPI 1356365928

Payments from drug & device makers

$24,508in general payments, 2019–2025

Across 1,289 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Biogen$2K
  • EMD Serono, Inc.$1K
  • Novartis$1K
  • AstraZeneca$961
  • UCB, Inc.$880
  • plus $15K from 54 others

What the payments were for

  • Speaking & faculty fees$440%
  • Food & beverage$24,32099%
  • Education$1441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)210$3,171
Biogen90$1,644
EMD Serono, Inc.58$1,248
Novartis66$1,208
AstraZeneca(2 entities)49$961
UCB, Inc.37$880
Eisai Inc.37$856
Pfizer38$774
Lundbeck LLC32$725
Lilly USA, LLC31$715
Otsuka America Pharmaceutical, Inc.32$699
SK Life Science, Inc.33$670
Neurocrine Biosciences, Inc.24$615
Upsher-smith Laboratories LLC39$585
Sanofi29$580
CSL Behring24$574
Acadia Pharmaceuticals Inc25$533
Sunovion Pharmaceuticals Inc.36$513
Teva Pharmaceuticals USA, Inc.35$490
Johnson & Johnson24$443
Avanir Pharmaceuticals, Inc.21$426
MDD US Operations, LLC29$423
TG Therapeutics, Inc.18$379
Supernus Pharmaceuticals, Inc.28$358
Amgen(2 entities)18$340
Axsome Therapeutics, Inc.10$319
Alnylam Pharmaceuticals Inc.12$281
Neurelis, Inc.15$274
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)10$251
Argenx US, Inc.9$223
Alkermes, Inc.8$205
Banner Life Sciences, LLC10$198
Biohaven Pharmaceuticals, Inc.9$187
Akcea Therapeutics, Inc.10$187
E.r. Squibb & Sons, L.L.C.4$180
Sumitomo Pharma America, Inc.13$178
Vanda Pharmaceuticals Inc.11$175
Livanova USA, Inc.3$170
Biohaven Pharmaceutical Holding Company Ltd.10$169
Amneal Pharmaceuticals LLC6$134
Bristol Myers Squibb8$130
Adamas Pharmaceuticals, Inc.6$113
Almatica Pharma LLC6$107
Catalyst Pharmaceuticals, Inc.6$105
Grifols USA, LLC4$77
Avion Pharmaceuticals4$76
Jazz Pharmaceuticals Inc.3$69
Cycle Pharmaceuticals Inc3$64
Portola Pharmaceuticals, LLC3$61
Takeda Pharmaceuticals U.S.A., Inc.3$58
Mallinckrodt Enterprises LLC3$56
Neos Therapeutics, LP3$55
Corium, LLC2$45
Acorda Therapeutics, Inc3$44
Noven Therapeutics, LLC2$39
Impel Pharmaceuticals Inc.2$37
Bausch Health US, LLC2$37
Ipsen Biopharmaceuticals, Inc2$36
Revance Therapeutics, Inc.1$36
Vertical Pharmaceuticals, LLC2$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,508 in reported general payments places this provider in the 70th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$78,279
Medicare patients
231
Services billed
630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5070$721,092
IngrezzaValbenazine Tosylate13$104,927
AptiomEslicarbazepine Acetate24$68,989
BotoxOnabotulinumtoxina18$26,416
XareltoRivaroxaban28$25,226
Emgality PenGalcanezumab-Gnlm25$20,699
NuedextaDextromethorphan Hbr/Quinidine13$20,404
Nurtec OdtRimegepant Sulfate13$12,981
Memantine Hcl275$9,485
Levetiracetam178$6,386
Carbidopa-LevodopaCarbidopa/Levodopa140$6,217
Lacosamide50$5,850
Gabapentin352$4,327
Pregabalin236$3,480
Lamotrigine126$3,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$574$721,09270 claims
Neurocrine Biosciences, Inc.Ingrezza$615$104,92713 claims
Sunovion Pharmaceuticals Inc.Aptiom$513$68,98924 claims
AbbVieBotox$3,171$26,41618 claims
Johnson & JohnsonXarelto$443$25,22628 claims
Avanir Pharmaceuticals, Inc.Nuedexta$426$20,40413 claims
PfizerNurtec Odt$774$12,98113 claims
Upsher-smith Laboratories LLCTopiramate$585$1,60687 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 361 neurology providers in Tennessee.

Other neurology in Hermitage

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →